Matches in SemOpenAlex for { <https://semopenalex.org/work/W3211978889> ?p ?o ?g. }
Showing items 1 to 95 of
95
with 100 items per page.
- W3211978889 endingPage "3907" @default.
- W3211978889 startingPage "3907" @default.
- W3211978889 abstract "Abstract Introduction Allogeneic hematopoïetic stem cell transplantation (HSCT) is the only established curative therapy for patients (pts) with sickle cell disease (SCD). It is mostly performed in children 1, due to higher risk of graft-versus-host disease (GVHD) and transplant related mortality in adults. Different approaches have been developped to improve tolerance of transplant in adults: use of reduced intensity conditioning (RIC) regimens 2 and intensive immunosuppression to avoid GVHD. Here, we have studied the impact of such approaches on immune reconstitution in adolescents and adults transplanted for SCD. Patients and methods We report 39 transplants in adolescents and adults, performed in Saint Louis hospital from 2008 to 2020: 25 were matched related transplants (MRT) and 14 haplo-identical related transplant (HRT). In MRT, conditioning was myeloablative (MAC) in 15 pts (busulfan, cyclophosphamide, rabbit anti-thymoglobulin (ATG) 20 mg/kg) and non myeloablative (NMA) in 10 pts (alemtuzumab 1 mg/kg, 3 Gy total body irradiation (TBI)). In MAC transplants, stem cell source was bone marrow and post-transplant immunosuppression was methotrexate and cyclosporine. In NMA transplants, stem cell source was peripheral blood cells with post-transplant immunosuppression by sirolimus. In the 14 HRT, the conditioning was reduced (cyclophosphamide, thiotepa, fludarabine, 2 Gy TBI, ATG 4.5 mg/kg), stem cell source was bone marrow and GVHD prophylaxis was ensured by post-transplant cyclophosphamide (100 mg/kg), sirolimus and mycophenolate mofetil. Results Median age at transplant was 17 years (y) old (range (r) 14-39). With a median follow-up of 3.6 y, the 2-y overall survival and survival without SCD were 97% (IC95%: 0.92-1) and 92% (IC95%: 0.83-1) respectively: no event after MRT, 1 death of GVHD and 2 graft rejections after HRT. The acute GVHD grade II-IV rate was 33%: 21% after HRT, 13% after MAC MRT and 0% after NMA MRT. Chronic GVHD occured in 3 pts (8%): severe in 1 HRT and mild in 2 MAC MRT. At 6 months, the blood chimerism evaluated in the 36 patients alive without rejection, was more often mixed (5 to 95% of donor) after NMA MRT (100%) versus MAC MRT (40%, p = 0.003) and HRT (18%, p < 0.001). Total lymphocytes (TL) counts increased rapidly in HRT and MAC MRT with a normalization from 3 months post-transplant. In contrast, NMA MRT experienced a slower recovery: at 6 months, median count was 1039/mm3 (r 463-1767) compared to 2071/mm3 (r 882-5985, p = 0.002) after MAC MRT and 2382/mm3 (r 676-3978, p = 0.005) after HRT. After NMA MRT, TL counts remained lower than normal values up to 12 months with a median of 1195/mm3 (r 870-3210) (Figure 1A). HRT displayed a rapid normalization of CD4 counts with a 3-month median count of 645/mm3 (r 350-1076) higher than reported after MRT (p < 0.001). Evolution of CD4 counts was similar after NMA and MAC MRT. They were lower than normal values during the first 12 months: median 364/mm3 and 388/mm3 respectively at 12 months (p = 0.25) (Figure 1B). From 3 months post-transplant, CD8 counts reached normal values after MAC MRT (314/mm3, r 108-2175) and were superior to normal after HRT (1335/mm3, r 66-4529), with a significant difference between HRT and MRT (p = 0.003). After NMA MRT, there was a trend for lower 3-month CD8 counts compared to MAC MRT: median of 107/mm3 (r 18-631, p = 0.08). CD8 counts remained under normal values after NMA MRT up to 12 months post-transplant (Figure 1C). From 3 to 6 months, CD4 and CD8 were mostly memory, with only 3.2% (r 0.1%-20.6%) and 6.2% (r 2.1%-11.2%) of CD45RA+ CCR7+ naïve CD8+ and CD4+ respectively. In the 3 groups NK cell counts reached normal values after 3 months. B lymphocytes counts normalized in the first months post-transplant except for patients who received rituximab for EBV reactivation. From 3 to 6 months, B lymphocytes were mostly naive: 98% of CD27- (r 92%-99%). Gammaglobuline levels were normal from 3 months in the 3 groups. Twelve (31%) pts were treated for a CMV and 6 (15%) for an EBV reactivation. No patient had CMV or adenovirus disease, or post-transplant lymphoproliferative disorder. Infections according to transplant types are detailed in figure 1D. Conclusion NMA MRT were associated with a delayed CD4 and CD8 recovery probably due to alemtuzumab. As previously reported 3, HRT displayed a rapid immune reconstitution. Despite use of serotherapy in the three modalities of transplant, the rate of viral infections remained acceptable without severe episode. Figure 1 Figure 1. Disclosures Pondarré: ADDMEDICA: Honoraria. Peffault De Latour: Jazz Pharmaceuticals: Honoraria; Pfizer: Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Research Funding; Amgen: Consultancy, Other, Research Funding; Alexion, AstraZeneca Rare Disease: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Research Funding. Boissel: CELGENE: Honoraria; Bristol-Myers Squibb: Honoraria, Research Funding; JAZZ Pharma: Honoraria, Research Funding; Incyte: Honoraria; Amgen: Consultancy, Honoraria, Research Funding; Novartis: Consultancy, Honoraria, Research Funding; Servier: Consultancy, Honoraria; SANOFI: Honoraria; PFIZER: Consultancy, Honoraria." @default.
- W3211978889 created "2021-11-22" @default.
- W3211978889 creator A5004581254 @default.
- W3211978889 creator A5047139286 @default.
- W3211978889 creator A5047305476 @default.
- W3211978889 creator A5050755416 @default.
- W3211978889 creator A5061098159 @default.
- W3211978889 creator A5074830346 @default.
- W3211978889 creator A5076734375 @default.
- W3211978889 creator A5076973611 @default.
- W3211978889 creator A5080390443 @default.
- W3211978889 creator A5080673678 @default.
- W3211978889 date "2021-11-05" @default.
- W3211978889 modified "2023-10-17" @default.
- W3211978889 title "Early Immune Reconstitution after Hematopoietic Stem Cell Transplantation for Adolescents and Adults with Sickle Cell Disease" @default.
- W3211978889 doi "https://doi.org/10.1182/blood-2021-147133" @default.
- W3211978889 hasPublicationYear "2021" @default.
- W3211978889 type Work @default.
- W3211978889 sameAs 3211978889 @default.
- W3211978889 citedByCount "0" @default.
- W3211978889 crossrefType "journal-article" @default.
- W3211978889 hasAuthorship W3211978889A5004581254 @default.
- W3211978889 hasAuthorship W3211978889A5047139286 @default.
- W3211978889 hasAuthorship W3211978889A5047305476 @default.
- W3211978889 hasAuthorship W3211978889A5050755416 @default.
- W3211978889 hasAuthorship W3211978889A5061098159 @default.
- W3211978889 hasAuthorship W3211978889A5074830346 @default.
- W3211978889 hasAuthorship W3211978889A5076734375 @default.
- W3211978889 hasAuthorship W3211978889A5076973611 @default.
- W3211978889 hasAuthorship W3211978889A5080390443 @default.
- W3211978889 hasAuthorship W3211978889A5080673678 @default.
- W3211978889 hasBestOaLocation W32119788891 @default.
- W3211978889 hasConcept C126322002 @default.
- W3211978889 hasConcept C141071460 @default.
- W3211978889 hasConcept C203014093 @default.
- W3211978889 hasConcept C2776694085 @default.
- W3211978889 hasConcept C2776755627 @default.
- W3211978889 hasConcept C2777408962 @default.
- W3211978889 hasConcept C2777630719 @default.
- W3211978889 hasConcept C2778880498 @default.
- W3211978889 hasConcept C2779015954 @default.
- W3211978889 hasConcept C2779263901 @default.
- W3211978889 hasConcept C2779968505 @default.
- W3211978889 hasConcept C2779972918 @default.
- W3211978889 hasConcept C2780252810 @default.
- W3211978889 hasConcept C2780611847 @default.
- W3211978889 hasConcept C28328180 @default.
- W3211978889 hasConcept C2909675724 @default.
- W3211978889 hasConcept C2911091166 @default.
- W3211978889 hasConcept C54355233 @default.
- W3211978889 hasConcept C71924100 @default.
- W3211978889 hasConcept C86803240 @default.
- W3211978889 hasConcept C90924648 @default.
- W3211978889 hasConceptScore W3211978889C126322002 @default.
- W3211978889 hasConceptScore W3211978889C141071460 @default.
- W3211978889 hasConceptScore W3211978889C203014093 @default.
- W3211978889 hasConceptScore W3211978889C2776694085 @default.
- W3211978889 hasConceptScore W3211978889C2776755627 @default.
- W3211978889 hasConceptScore W3211978889C2777408962 @default.
- W3211978889 hasConceptScore W3211978889C2777630719 @default.
- W3211978889 hasConceptScore W3211978889C2778880498 @default.
- W3211978889 hasConceptScore W3211978889C2779015954 @default.
- W3211978889 hasConceptScore W3211978889C2779263901 @default.
- W3211978889 hasConceptScore W3211978889C2779968505 @default.
- W3211978889 hasConceptScore W3211978889C2779972918 @default.
- W3211978889 hasConceptScore W3211978889C2780252810 @default.
- W3211978889 hasConceptScore W3211978889C2780611847 @default.
- W3211978889 hasConceptScore W3211978889C28328180 @default.
- W3211978889 hasConceptScore W3211978889C2909675724 @default.
- W3211978889 hasConceptScore W3211978889C2911091166 @default.
- W3211978889 hasConceptScore W3211978889C54355233 @default.
- W3211978889 hasConceptScore W3211978889C71924100 @default.
- W3211978889 hasConceptScore W3211978889C86803240 @default.
- W3211978889 hasConceptScore W3211978889C90924648 @default.
- W3211978889 hasIssue "Supplement 1" @default.
- W3211978889 hasLocation W32119788891 @default.
- W3211978889 hasOpenAccess W3211978889 @default.
- W3211978889 hasPrimaryLocation W32119788891 @default.
- W3211978889 hasRelatedWork W2599431336 @default.
- W3211978889 hasRelatedWork W2615902868 @default.
- W3211978889 hasRelatedWork W2620956092 @default.
- W3211978889 hasRelatedWork W2754125581 @default.
- W3211978889 hasRelatedWork W2906074775 @default.
- W3211978889 hasRelatedWork W2912754533 @default.
- W3211978889 hasRelatedWork W2952972739 @default.
- W3211978889 hasRelatedWork W2979354104 @default.
- W3211978889 hasRelatedWork W3211978889 @default.
- W3211978889 hasRelatedWork W4310956126 @default.
- W3211978889 hasVolume "138" @default.
- W3211978889 isParatext "false" @default.
- W3211978889 isRetracted "false" @default.
- W3211978889 magId "3211978889" @default.
- W3211978889 workType "article" @default.